Beating Cancer with a One-Two Punch: How Combining Ablation Therapies Could Change Everything
"New research explores the synergistic power of radiofrequency ablation (RFA) and irreversible electroporation (IRE) to enhance tumor destruction."
For decades, the fight against cancer has been defined by a relentless search for more effective and less invasive treatments. Among the arsenal of tools available to oncologists, ablation therapies have emerged as promising options for targeting and destroying tumors. Now, groundbreaking research suggests that combining two of these therapies – radiofrequency ablation (RFA) and irreversible electroporation (IRE) – could deliver a powerful one-two punch against cancer cells.
Both RFA and IRE are image-guided techniques, meaning doctors use imaging technology to precisely target tumors. RFA uses heat generated by high-frequency alternating current to kill cancer cells, while IRE employs high-voltage electrical pulses to create pores in cell membranes, leading to cell death. While both methods have shown success in treating various tumors, limitations exist, particularly when dealing with large tumors or those located near major blood vessels.
But what if these two therapies could work together, each overcoming the limitations of the other? That's the question researchers at Shanghai University and the University of Saskatchewan sought to answer. Their in vitro study, using a 3D cervical cancer cell model, has revealed the potential for significant tumor ablation enhancement when RFA and IRE are strategically combined.
A Fast-Growing Field Behind Soaring Cancer Numbers
Cancer remains a highly prevalent global disease, with Cancer Australia statistics for 2022 reporting 162,163 new cancer cases diagnosed in Australia alone, underscoring the substantial burden the disease places on health systems. In response, the tumor ablation market is expanding rapidly, with one report projecting it will reach a value of USD 7.47 billion by 2035. Regional data reinforce the scale of adoption: Europe's tumor ablation market reached USD 0.45 billion in 2024, accounting for roughly 30% of global share, while radiofrequency ablation led the technology segment with a 42% share that year, supported by widespread clinical adoption and proven treatment effectiveness. Behind these figures is growing clinical confidence, as ablation is considered a curative treatment option for small liver cancers, akin to surgical resection, while technological advances in ablation devices continue to improve accuracy, portability, and cost-effectiveness.
Standardized Tools with Real Size and Location Limits
Global guidelines for tumor ablation aim to standardize treatment, and they place considerable weight on the size of the tumor, its location, and the individual patient's needs when deciding whether ablation is appropriate. The method is versatile, and it can be performed either under direct surgical vision or through image-guided approaches depending on the anatomical location of the target. Yet ablation carries recognized limitations, and the review literature notes that it may even be curative only in selected patients with small primary or secondary tumors, including some liver tumors, rather than a universal option. Where it excels is in defined roles such as treating oligometastatic disease and oligoprogression, and ongoing work in areas like bronchoscopic tumor ablation continues to refine which patients and tumor profiles benefit most.
From Needle Probes to Whole-Body Applications
The foundational technique, radiofrequency ablation (RFA), uses high-energy radio waves to heat and destroy tumors, delivered through a thin, needle-like probe that is inserted through the skin and advanced until its tip sits inside the tumor. Early experience built around precise, image-guided delivery: at MSKCC, for example, ablation for kidney tumors became a good option instead of surgery for removing small kidney tumors up to 4 centimeters, with CT imaging guiding a thin needle that uses extreme temperatures to destroy cancer cells. Over time, ablation programs expanded to treat tumors arising in the lung, liver, kidney, adrenal glands, lymph nodes, bones and soft tissues, and prostate. The reach of the approach also extended to symptom relief, with bone tumor ablation reported to offer those living with painful and often debilitating bone tumors much-needed relief.
The Science Behind the Synergy
The study explored different sequences of applying RFA and IRE to the 3D tumor model. Researchers tested three RFA temperatures (43, 50, and 60 °C) and three IRE voltage settings (350, 700, and 1050 V/cm). The results were striking: both RFA enhanced IRE and IRE enhanced RFA, leading to significantly larger ablation zones compared to using either therapy alone. Think of it like this: RFA can weaken the tumor cells, making them more susceptible to IRE, or vice versa. This synergistic effect could be a game-changer in cancer treatment.
- Enhanced Ablation Zone: Combining RFA and IRE leads to a significantly larger area of tumor destruction.
- Sequence Matters: The order in which RFA and IRE are applied affects the overall effectiveness.
- Increased Conductivity: Preliminary RFA or IRE treatment increases the electrical conductivity of the tumor.
- Repeat Injury: The transitional zone, initially injured by one treatment, is further compromised by the second.
New Research Targets Bigger, Harder-to-Reach Tumors
The latest published research on tumor ablation shows the field pushing past familiar boundaries, with investigators reporting that ablation may be a more effective method for managing large lesions, as well as those that are difficult to ablate. A significant thread of current research centers on how ablation interacts with the immune system, and Frontiers has launched a community series on tumor ablation and immunity (Volume II), an open call for contributions examining the intersection of tumor ablation and immune response. The volume of new literature indexed under the tumor ablation keyword continues to grow, spanning hot topics, top authors, and the most-cited documents in the field. Together, these efforts signal a shift toward not just destroying tissue but understanding the biological consequences of that destruction.
Known Risks, Real-World Failures, and Contested Claims
Ablation is not without failure modes, and one of the most serious is cryoshock, a systemic inflammatory response mainly limited to ablation of hepatocytes, which the research literature links to the extent of cryoablated liver tissue. In sheep and rat studies, the frequency of systemic inflammatory response correlated positively with the amount of ablated liver tissue, with animals having more than 35% of ablated tissue presenting an elevated risk. Long-term outcome data are also under ongoing scrutiny, with specialists such as Jeffrey A. Cadeddu, MD, reviewing reliable and reproducible 5+ year data comparing ablation effectiveness for kidney tumors. At the same time, fringe claims circulate, including one source reporting an intratumoral chlorine dioxide system said to ablate tumors by exploiting tumor vasculature, a claim that has not been established in mainstream clinical literature.
Heat-Based Rivals and Imaging Feedback Face Off
Radiofrequency ablation is currently established as the standard method for local tumor treatment, and it is recommended for patients with early-stage hepatocellular carcinoma when surgical options are precluded. The technique works by employing high-frequency alternating currents to produce frictional heat, resulting in coagulative necrosis of the targeted tissue, and comparative work contrasts it with microwave ablation, which heats tissue through a different energy mechanism. Image-guided thermal ablation in its various forms, including RFA, microwave ablation, and laser ablation, has increasingly been applied as an alternative for patients with papillary thyroid microcarcinoma who are at surgical risk or refuse surgery or active surveillance. Research also compares how treatment is monitored, with one study evaluating the accuracy of PRFS-based MR thermometry against an alternative T1 thermometry model for predicting tissue necrosis during MRI-guided laser ablation of human liver.
A Promising Future for Cancer Treatment
These findings offer a promising avenue for improving cancer treatment, especially for large tumors or those located near major blood vessels. While this study was conducted in vitro, the results warrant further investigation in in vivo models and, eventually, clinical trials. Combining RFA and IRE could potentially overcome the limitations of each individual therapy, leading to more complete and effective tumor ablation. The key will be optimizing the treatment protocols and identifying the ideal candidates for this combined approach. This research provides a crucial step forward in the ongoing quest to conquer cancer and improve the lives of patients.
When Experts Put the Pieces Together
As the evidence base matures, expert consensus documents are emerging to standardize care around combined approaches, including a consensus on perioperative management for patients with lung cancer undergoing co-ablation system therapy and a parallel consensus on clinical practice for multi-model ablation of liver malignant tumors. In interventional radiology practice, frontline specialists point to real procedural hurdles, and interviews with figures such as the physician who has performed the highest number of spine tumor ablations in the US highlight major challenges in the technique and the strategies used to overcome them. Market researchers echo this reliance on expert input, with analysts working closely with tumor ablation experts to validate gathered data before presenting it to clients. The convergence of clinical consensus-building and practitioner experience suggests a field actively codifying what works.
An Optimistic Roadmap with Widely Differing Forecasts
The future outlook for the interventional tumor ablation market is broadly optimistic, driven by technological innovation, the rising incidence of cancer, and a global shift toward minimally invasive therapies. Analysts point to a continued shift toward advanced, more patient-friendly treatment options, and radiofrequency ablation remains a dominant technology, accounting for approximately 34% of the market share in 2024. Notably, market size projections vary considerably among reports, with figures ranging from a projected USD 2.66 billion by 2030 at an 8.5% CAGR to estimates of approximately USD 12.5 billion by 2034 from a 2024 base near USD 6.7 billion, so specific forecasts should be read with caution. The consistent theme across analyses, however, is sustained growth driven by both demographic demand and incremental technical improvement.
Vessels, Microenvironments, and the Biology of Resistance
Ablating tumors is not purely a mechanical exercise, and one of the most intricate challenges is ablating tumors located near major blood vessels, where the heat sink effect, risks of vascular damage, and other technical limitations complicate treatment. Beyond procedural hurdles, the immunosuppressive tumor microenvironment presents a substantial challenge to current systemic therapies, in part because of a lack of available tumor antigen, dense stroma, an abundance of immunosuppressive cells and cytokines, and poor antigen presentation. These biological barriers explain why combining local ablation with immunomodulatory strategies has become a focus of investigation. The commercial landscape reflects the stakes, with the interventional tumor ablation market already valued in the billions and projected to grow at a CAGR of 11.5% from 2026 to 2033.
Guided by Augmented Reality, Recovering Patients
New guidance technology is reshaping how physicians visualize the human body's obstacle course of organs and vessels during ablation, with 3D augmented reality (AR) able to make anatomy more clearly visible by enhancing real-world environments with computer-generated perceptual information. The patient impact of these procedures is measurable in real clinical data: a report on laser ablation of abnormal neurological tissue described 131 primary and 92 metastatic ablated tumors, with most primary tumors being high-grade gliomas (80.9%) and metastatic patients facing recurrence (50.6%) or radiation necrosis (40%). The same report found a median postprocedure hospital stay of 33.4 hours, ranging widely from 12.7 to 733.4 hours, showing that even minimally invasive treatments carry meaningful recovery burdens for some patients. Together these figures ground the promise of ablation technology in the day-to-day experience of those undergoing treatment.